You just read:

New Post-Hoc Analyses Report Early Symptomatic Improvement in Moderately to Severely Active Ulcerative Colitis or Crohn's Disease Patients Taking Entyvio® (vedolizumab), Particularly in Biologic-Naïve Patients

News provided by

Takeda Pharmaceutical Company Limited

16 Oct, 2017, 13:06 BST